RxDoctor Payments Data

Amanda Umlandt

Optometrist · Grundy, VANPI 1720217854

Payments from drug & device makers

$2,236in general payments, 2019–2025

Across 34 payments — averaging $65.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Coopervision Inc.$829
  • Alcon$497
  • AbbVie$237
  • Lumenis BE Inc$147
  • Carl Zeiss Meditec USA, Inc.$136
  • Mallinckrodt Hospital Products Inc.$125
  • plus $265 from 5 others

What the payments were for

  • Travel & lodging$74433%
  • Food & beverage$1,49267%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,236 in reported general payments places this provider in the 75th percentile of 1,230 optometrist providers in Virginia.

See all optometrist providers in Virginia

Medicare billing

Part B allowed, 2024
$69,376
Medicare patients
282
Services billed
3,017

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine49$53,271
Cyclosporine19$9,370
LumiganBimatoprost12$6,720
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol22$4,187
Latanoprost248$2,653
Tobramycin-DexamethasoneTobramycin/Dexamethasone48$2,375
Prednisolone Acetate52$2,245
Travoprost11$1,464
Ketorolac Tromethamine29$1,155
MoxifloxacinMoxifloxacin Hcl23$765
ErythromycinErythromycin Base34$654
Timolol Maleate63$580
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat13$155
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha13$153

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$237$59,99161 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,230 optometrist providers in Virginia.

Other optometrist in Grundy

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →